CheckMate 025: A randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) Meeting Abstract
| Authors: | Sharma, P.; Escudier, B.; McDermott, D. F.; George, S.; Hammers, H. J.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Procopio, G.; Plimack, E. R.; Castellano, D.; Gurney, H.; Donskov, F.; Bono, P.; Wagstaff, J.; Gauler, T. C.; Ueda, T.; Xu, L. A.; Waxman, I. M.; Motzer, R. J. |
| Abstract Title: | CheckMate 025: A randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) |
| Meeting Title: | 18th European Cancer Conference (ECCO 18) |
| Journal Title: | European Journal of Cancer |
| Volume: | 51 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2015 Sep 25-29 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-09-01 |
| Start Page: | S708 |
| Language: | English |
| ACCESSION: | WOS:000361887403249 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(16)31926-8 |
| Notes: | Meeting Abstract: 3LBA -- Source: Wos |
